全文获取类型
收费全文 | 52592篇 |
免费 | 3568篇 |
国内免费 | 1857篇 |
专业分类
耳鼻咽喉 | 946篇 |
儿科学 | 857篇 |
妇产科学 | 727篇 |
基础医学 | 7196篇 |
口腔科学 | 1013篇 |
临床医学 | 4495篇 |
内科学 | 6804篇 |
皮肤病学 | 659篇 |
神经病学 | 1586篇 |
特种医学 | 2177篇 |
外科学 | 11264篇 |
综合类 | 7347篇 |
预防医学 | 1857篇 |
眼科学 | 418篇 |
药学 | 4129篇 |
12篇 | |
中国医学 | 1037篇 |
肿瘤学 | 5493篇 |
出版年
2023年 | 387篇 |
2022年 | 934篇 |
2021年 | 1331篇 |
2020年 | 1185篇 |
2019年 | 918篇 |
2018年 | 1062篇 |
2017年 | 1265篇 |
2016年 | 1350篇 |
2015年 | 1530篇 |
2014年 | 2916篇 |
2013年 | 3089篇 |
2012年 | 3096篇 |
2011年 | 3415篇 |
2010年 | 2903篇 |
2009年 | 3124篇 |
2008年 | 3185篇 |
2007年 | 3217篇 |
2006年 | 3025篇 |
2005年 | 2707篇 |
2004年 | 2167篇 |
2003年 | 1988篇 |
2002年 | 1539篇 |
2001年 | 1497篇 |
2000年 | 1317篇 |
1999年 | 1063篇 |
1998年 | 843篇 |
1997年 | 782篇 |
1996年 | 660篇 |
1995年 | 645篇 |
1994年 | 588篇 |
1993年 | 454篇 |
1992年 | 431篇 |
1991年 | 328篇 |
1990年 | 324篇 |
1989年 | 301篇 |
1988年 | 325篇 |
1987年 | 244篇 |
1986年 | 182篇 |
1985年 | 204篇 |
1984年 | 194篇 |
1983年 | 107篇 |
1982年 | 178篇 |
1981年 | 159篇 |
1980年 | 177篇 |
1979年 | 133篇 |
1978年 | 98篇 |
1977年 | 81篇 |
1976年 | 76篇 |
1973年 | 57篇 |
1972年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Archivos de bronconeumología》2022,58(12):802-808
IntroductionThe main aim of this study was to assess the utility of differential white cell count and cell population data (CPD) for the detection of COVID-19 in patients admitted for community-acquired pneumonia (CAP) of different etiologies.MethodsThis was a multicenter, observational, prospective study of adults aged ≥18 years admitted to three teaching hospitals in Spain from November 2019 to November 2021 with a diagnosis of CAP. At baseline, a Sysmex XN-20 analyzer was used to obtain detailed information related to the activation status and functional activity of white cells.ResultsThe sample was split into derivation and validation cohorts of 1065 and 717 patients, respectively. In the derivation cohort, COVID-19 was confirmed in 791 patients and ruled out in 274 patients, with mean ages of 62.13 (14.37) and 65.42 (16.62) years, respectively (p < 0.001). There were significant differences in all CPD parameters except MO-Y. The multivariate prediction model showed that lower NE-X, NE-WY, LY-Z, LY-WY, MO-WX, MO-WY, and MO-Z values and neutrophil-to-lymphocyte ratio were related to COVID-19 etiology with an AUC of 0.819 (0.790, 0.846). No significant differences were found comparing this model to another including biomarkers (p = 0.18).ConclusionsAbnormalities in white blood cell morphology based on a few cell population data values as well as NLR were able to accurately identify COVID-19 etiology. Moreover, systemic inflammation biomarkers currently used were unable to improve the predictive ability. We conclude that new peripheral blood biomarkers can help determine the etiology of CAP fast and inexpensively. 相似文献
2.
Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit 下载免费PDF全文
Sharareh SeifiBabak SalimiZahra Esfahani-MonfaredRamin RadmaneshSaeed YaghoubifardSara TalebianpourAdnan Khosravi 《Asian Pacific journal of cancer prevention》2022,23(4):1155-1158
Background: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). Methods: Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients. Patients with EGFR mutation received Erlova at 150 mg/day as first line treatment. Primary endpoint was progression free survival (PFS). Results: About 21% (n=109) cases had EGFR mutation. Most EGFR mutations were occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about 88%. Most frequent treatment related adverse events was skin rash. Conclusion: Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors. 相似文献
3.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
4.
5.
6.
《Survey of ophthalmology》2023,68(5):940-956
Congenital aniridia is a panocular disorder that is typically characterized by iris hypoplasia and aniridia-associated keratopathy (AAK). AAK results in the progressive loss of corneal transparency and thereby loss of vision. Currently, there is no approved therapy to delay or prevent its progression, and clinical management is challenging because of phenotypic variability and high risk of complications after interventions; however, new insights into the molecular pathogenesis of AAK may help improve its management. Here, we review the current understanding about the pathogenesis and management of AAK. We highlight the biological mechanisms involved in AAK development with the aim to develop future treatment options, including surgical, pharmacological, cell therapies, and gene therapies. 相似文献
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(10):1143-1150
PurposeTo report the 5-year results from the Pivotal Multicenter Trial of Ultrasound-Guided Percutaneous Arteriovenous Fistula (pAVF) Creation for Hemodialysis Access.Materials and MethodsThe retrospective review of 107 intent-to-treat (ITT) patients from the pivotal trial provided a long-term follow-up population (LTP) of 85 patients with a median follow-up duration of 50 months (range, 12–60 months). Data evaluated in the LTP group were fistula maturation and usage, secondary procedures, and complications. The Kaplan-Meier analysis of primary patency, assisted primary patency, cumulative patency, and functional patency (time from 2-needle cannulation to abandonment) were performed for the ITT population.ResultsIn the LTP, 99% (84 of 85) of fistulae were mature, with 99% (78 of 79) of patients requiring hemodialysis using their pAVF. Sustained fistula use (2-needle cannulation at the prescribed rate, 2 of 3 sessions) was achieved in 92% (78 of 85) of patients, with 7 patients not using their pAVF because they were not on dialysis (n = 4), were on peritoneal dialysis (n = 2), and refused to use fistula (n = 1). Fistula maintenance was required in 31.8% (27 of 85) of patients and included fistula dysfunction (21.2%), thrombosis (5.9%), cannulation injury (12.9%), and arm swelling (4.7%). The number of procedures performed per patient per year to maintain function and patency was 0.32 (91 of 288) for years 2–5. The cumulative patency rates were 89.5%, 88.4%, 88.4%, 85.6%, and 82.0% for years 1, 2, 3, 4, and 5, respectively. The functional patency was 91.8% at the end of the study. There were no major complications related to pAVF during the long-term follow-up.ConclusionsPercutaneous fistulae have provided clinically effective and durable access for hemodialysis with low complications. The continued use and evaluation of pAVF are warranted. 相似文献
9.
目的 探讨蜂巢提取物Elixir-X对自然衰老及辐射衰老小鼠的影响,为Elixir-X的进一步研发提供药理学基础。方法 采用小鼠肝脏切除术建立自然衰老小鼠模型,将其分为空白对照组、Elixir-X组、白藜芦醇组及模型组,连续给药7 d后,检测小鼠70%肝脏切除后的再生过程中,衰老细胞、肝脏功能恢复与肝脏再生的变化,观察Elixir-X对自然衰老的影响;采用60CO辐射法建立辐射衰老小鼠模型,将其分为模型组、空白对照组、白藜芦醇组、Elixir-X高、低剂量组,通过检测小鼠肠隐窝干细胞再生、小肠绒毛结构以及衰老细胞的变化,对比不同剂量Elixir-X对辐射后衰老的影响。结果 在肝脏切除术的小鼠模型中,Elixir-X组的肝功能水平明显低于模型组的肝脏自然再生小鼠,显著促进了肝功能恢复(P<0.05);同时与模型组相比,Elixir-X组清除了肝脏切除后再生过程中产生的衰老细胞(P<0.05),Ki-67的着色斑块明显增加,促进肝脏的再生,且肝血窦的扫描电镜影像结果中Elixir-X组肝血窦再生加快。60CO辐照小鼠模型中,与模型组相比,Elixir-X组有效促进辐照后肝脏功能恢复(P<0.05),Elixir-X高剂量组体重也恢复到正常水平,与空白对照组无显著差异;与模型组相比,Elixir-X低剂量组小肠的β-Gal着色细胞减少,Elixir-X高剂量组甚至能更有效地减少衰老细胞(P<0.05);小肠HE染色的结果中,Elixir-X组小肠绒毛结构得到恢复;Ki-67的IHC染色中,与模型组相比,Elixir-X组着色板块更多,且着色区域都在肠隐窝干细胞位置。结论 Elixir-X能有效清除肝脏切除术引起的自然衰老与辐射引起的损伤性衰老细胞,对衰老具有显著地抑制作用。 相似文献
10.